Purpose The aim of this study was to investigate relationships between the immunohistochemical results and radioiodine scan and 18
Introduction
The prognosis of well-differentiated thyroid cancer (DTC) is favorable, with a 10-year survival rate exceeding 90 % [1] . However, up to 20 % of patients with DTC develop locoregional recurrence including cervical lymph node metastases, and 8 % of patients with recurrence will eventually succumb to the disease [2] . Although one of the main characteristics of DTC is its ability to trap radioiodine due to the expression of sodium-iodide symporter (NIS), approximately 15-30 % of metastatic cancer lesions lose this ability and thus show no radioiodine uptake on post-therapeutic 131 I scans [3] [4] [5] . This lack of an ability to accumulate radioiodine is problematic in patients with recurrent lymph nodes; hence, imaging modalities other than a radioiodine scan might be necessary in DTC patients with recurrent cervical nodes. Furthermore, conventional imaging modalities such as neck ultrasonography and computed tomography (CT) have also shown moderate sensitivity with a range of 63-82 % [6, 7] . 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) is recommended in patients with radioiodine-negative DTC [8, 9] . Glucose transporter 1 (Glut-1) is known to be the most important glucose transporter in thyroid cancer cells and is also known to be related to 18 F-FDG uptake in various cancers [10] [11] [12] . Furthermore, some previous reports have been issued on the use of somatostatin receptor (SSTR)-targeted imaging in DTC patients with negative radioiodine uptake [9, 13] . However, no consensus exists concerning optimal imaging modalities for the follow-up of patients with recurrent cervical nodes. Although findings of radioiodine scans and 18 F-FDG PET can provide important information for planning further treatment and predicting prognosis, there are few studies to evaluate the relationship between the histopathological findings and radioiodine scan and 18 F-FDG PET findings. We considered that a deeper understanding of the relationships between the expressions of the pathological markers of DTC and the uptakes of various radiotracers would facilitate the imaging modality choice for the follow-up of DTC patients with recurrent neck nodes.
The objectives of this study were to evaluate the relationships between the expression levels of pathological markers [thyroglobulin (Tg), NIS, Glut-1, SSTR1 and SSTR2A] and radioiodine scan and 18 F-FDG PET findings in DTC patients with recurrent cervical nodal metastases.
Materials and Methods

Patients
This study was approved by our Institutional Review Board. F-FDG PET/CT scan and surgery was 74± 59 days. Scans were performed using a Gemini PET/CT scanner (Philips, Milpitas, CA). All patients were normoglycemic and fasted for at least 6 h before scans. Patients were injected with 5.18 MBq/kg of 18 F-FDG 1 h prior to imaging. Initially, a CT scan was performed at 80 mA and 140 kVp for attenuation correction, then an emission scan was performed from the skull base to the proximal thigh in one bed position for 3 min. Emission scan images were reconstructed onto a 128 × 128 matrix using an iterative algorithm (ordered subset expectation maximization), and attenuation correction was performed.
Mean time between the radioiodine scan and surgery was 124 ± 44 days. All patients discontinued replacement L-thyroxine (T 4 ) therapy 4 weeks before radioiodine administration and received replacement L-triiodothyronine (T 3 ) for up to 2 weeks before radioiodine administration. In addition, all patients followed a low-iodine diet from at least 2 weeks before radioiodine administration. At the time of radioiodine administration, serum thyroid-stimulating hormone (TSH) levels were higher than 30 IU/ml in all patients. Among 19 patients, 14 underwent a post-therapeutic 131 I scan, and scanning was performed 3-5 days after an oral administration of a I. All radioiodine scans were performed using a large-field-of-view gamma camera (ON 410, Ohio Nuclear, Solon, OH) equipped with a medium-energy parallel-hole collimator, and a 20 % symmetric window was centered at 364 KeV. Anterior and posterior images of the neck, chest and abdomen were obtained during all radioiodine scans, and a minimum of 100,000 counts were collected for each image. All 18 F-FDG PET/CT and radioiodine scan images were retrospectively reviewed by experienced nuclear medicine physicians with consensus. The 18 F-FDG uptakes and radioiodine uptake of the resected cervical lymph nodes on the scan images were visually assessed. The neck lymph nodes that showed higher 18 F-FDG uptake than surrounding neck tissue uptake were classified as lymph nodes with positive 18 F-FDG uptake, and the neck lymph nodes that showed similar uptake to surrounding neck tissue uptake were classified as lymph nodes with negative 18 F-FDG uptake. Furthermore, focal increased 131 I uptake in the neck area was classified as lymph nodes with positive 131 I uptake. In patients with multiple lymph nodal metastases who underwent 18 F-FDG PET/CT, the lymph node that showed the most intense 18 F-FDG uptake was selected for the analysis, and the lymph node specimen that corresponded to the anatomical location on PET/CT was selected for immunohistochemical analysis. In patients with multiple lymph nodal metastases who underwent a 131 I scan, the lymph node that had the largest metastatic foci at the area of 131 I uptake was selected for the analysis.
Immunohistochemistry
All specimens from the surgical resection of recurrent cervical lymph nodes were stained with hematoxylin and eosin and reviewed by an experienced pathologist to confirm the presence of recurrent thyroid cancer. Immunohistochemical staining in all 46 cases was performed automatically based on the conventional streptavidin-biotin-peroxidase method using the TechMate™ 500 Plus (DAKO, Glostrup, Denmark) according to the manufacturer's protocol. The primary antibodies used were as follows: Tg (1:200, TGB04+TGB05, Thermo Scientific, CA), anti-hNIS (1:200, Clone FP5A, Thermo Scientific, CA), Glut-1 (1:200, C-20, Santa Cruz Biotechnology, Heidelberg, Germany), SSTR1 (1:100, BioTrend, Cologne, Germany) and SSTR2A (1:150, BioTrend, Cologne, Germany). Cells were scored as 0, 1 or 2 (negative, weak, strong) for Glut-1 or 0, 1, 2 or 3 (negative, mild, moderate, strong) for Tg according to their staining intensities. For NIS, SSTR1 and SSTR2A, percentages of stained cells were determined, and a final histochemical score (H-score) was calculated by summing the products of staining intensities [scored as 0 or 1 (negative and positive, respectively) for SSTR2A and as 0, 1 or 2 (negative, weak, strong) for NIS and SSTR1] and their distributions (0-100 %). Tg, NIS, SSTR1 and SSTR2A antibodies showed positivity in the cytoplasm, and Glut was positive in the cytoplasm and cytoplasmic membranes with luminal accentuation. Normal thyroid follicular cells (for Tg and NIS), red blood cells (for Glut) and normal pancreatic islet cells (for SSTR1 and SSTR2A) served as internal positive controls.
Statistical Analyses
For the purpose of statistical analysis, the expressions of Tg, Glut-1, NIS, SSTR1 and SSTR2A were dichotomized; Tg immunoexpression was divided into two groups of staining intensities:≥2 (score=2, 3) or ≤1 (score=0, 1). Glut-1 expression was categorized as positive (score=1, 2) or negative (score=0). In addition, to evaluate the significance of the luminal accentuation of Glut-1 expression, the expression of Glut-1 was also categorized as membranous with or without luminal accentuation. The expressions of NIS, SSTR1 and SSTR2A were dichotomized about the half maximal H-scores for each marker (100 for SSTR1 and 50 for SSTR2A). The cutoff value used for NIS was determined by considering the mean H-score because NIS expressions tended to be weak. The chi-square test and Fisher's exact test were performed to determine differences between the frequency of positive 18 F-FDG or radioiodine uptakes in the two groups for each pathological marker. All statistical tests were performed using SPSS (version 15.0; SPSS Inc.). P-values<0.05 were considered statistically significant.
Results
F-FDG PET/CT and Radioiodine Scan Results and Immunohistochemical Findings
All 46 patients had a diagnosis of recurrent papillary thyroid cancer (PTC). In the 38 patients who underwent 18 F-FDG PET/CT, 21 (55 %) showed positive 18 F-FDG uptake in recurrent cervical nodes, while the remaining 17 (45 %) were negative for 18 F-FDG uptake. In the 19 patients who underwent a radioiodine scan, 6 (32 %) showed positive radioiodine uptake in recurrent lesions, and the remaining 13 (68 %) showed negative uptake. Of these six patients with p o s i t i v e r a d i o i o d i n e u p t a k e , f o u r u n d e r w e n t a post-therapeutic scan, and the other two underwent a diagnostic scan. Furthermore, of the 13 patients with negative uptake, 10 underwent a post-therapeutic scan, and 3 underwent a diagnostic scan.
The results of immunohistochemical staining for Tg, NIS, Glut-1, SSTR1 and SSTR2A are shown in Table 2 . Among 46 study subjects, 39 (85 %) showed moderate or strong (staining intensity=2 or 3) Tg expression, and only 2 and 9 showed strong Glut-1 expression in the cytoplasm and cytoplasmic membrane, respectively. NIS expression tended to be weak among study subjects (mean H-score=54±42), and a cutoff H-score of 50 was used for NIS. SSTR2A expression was only mild (staining intensity=0 or 1), and overall expression of SSTR2A in enrolled patients was weaker than that of SSTR1.
Relationships Between Table 3 . Recurrent cervical node 18 F-FDG uptake was found to be related to Tg expression and Glut-1 membranous expression with luminal accentuation. All patients with weak Tg expression (staining intensity=0 or 1) showed positive 18 F-FDG uptake (Fig. 1) , whereas only 45 % of patients with strong Tg expression (staining intensity=2 or 3) showed positive 18 F-FDG uptake (p=0.01). Cytoplasmic Glut-1 expression was not found to be associated with positive 18 F-FDG uptake. However, although a marginally significant relationship was found between Glut-1 expression with luminal accentuation and the proportion of patients with positive 18 F-FDG uptake (p=0.06), the proportion of patients positive for 18 F-FDG uptake among patients with Glut-1 membranous expression (staining intensity = 2) with luminal accentuation (75 %; Fig. 2 ) was two-fold higher than the proportion of patients with Glut-1 expression without luminal accentuation (38 %). In contrast, irrespective of luminal accentuation, the intensity of Glut-1 membranous expression was not found to be related to 18 F-FDG uptake (p=0.3). Furthermore, no relationship was found between the expressions of NIS, SSTR1 or SSTR2 and the number of patients with positive 18 F-FDG uptake (p>0.05). In patients with strong SSTR1 or SSTR2A expression, 40 and 38 %, respectively, were negative for 18 F-FDG uptake.
Relationship Between Radioiodine Scans and Immunohistochemistry
Relationships between radioiodine scan results and immunohistochemical results are shown in Table 4 . The proportion of patients with positive radioiodine uptake in recurrent cervical nodes was found to be significantly related to NIS and SSTR2A expression (p = 0.04 for all; Fig. 3 ) and to be Memb cytoplasmic membrane, Cyt cytoplasm, Glut-1 glucose transporter 1, NIS sodium-iodide symporter, SSTR somatostatin receptor marginally related to SSTR1 expression (p=0.06). Over 90 % of patients with weak NIS and SSTR1 expression and 100 % of patients with weak SSTR2 expression showed negative radioiodine uptake, but only 50-60 % of patients strongly expressing these markers showed positive radioiodine uptake. All three patients with weak Tg expression (staining intensity=0 or 1) were negative for radioiodine uptake. In addition, no relationship was found between the cytoplasmic or membrane expressions of Glut-1 and the proportion of patients showing radioiodine uptake (p>0.05).
Discussion
This study shows that all patients with weak Tg expression had positive 18 F-FDG uptake or negative radioiodine uptake, and positive radioiodine uptake was found to be related to the expressions of NIS and SSTR2A, which suggests that the uptakes of 18 F-FDG and radioiodine are associated with the differentiation of thyroid cancer cells. Furthermore, 18 F-FDG uptake was found to be related to the luminal accentuation of Glut-1 expression rather than the membrane expression of Glut-1.
In the present study, all cervical nodal metastases with weak Tg expression showed positive 18 F-FDG uptake or negative radioiodine uptake. It has been previously reported that the production and expression of Tg suggests a differentiated thyroid cancer phenotype and that anaplastic thyroid cancer shows significantly lower Tg expression than DTC [14, 15] . Papillary thyroid carcinomas can be classified as relatively well differentiated or as relatively less differentiated, and the relatively well-differentiated cancers show higher levels of NIS and Tg expression and a lower level of Glut-1 expression [16] . Accordingly, decreased Tg expression could imply an anaplastic change in papillary cancer. Thus, 18 F-FDG PET rather than a radioiodine scan should be adopted to follow-up patients with weak Tg expression.
Glut-1 expression is known to be related to a poor prognosis in thyroid cancer and to be significantly elevated in papillary thyroid cancers without radioiodine uptake [17, 18] . Moreover, previous studies have shown that Glut-1 expression in DTC is more often cytoplasmic than membranous [17, 19] . In the present study, it was also found that all 46 patients exhibited positive cytoplasmic Glut-1 expression and that 70 % exhibited positive membranous Glut-1 expression. Membranous Glut-1 expression is most prominent around necrotic cancer areas, and hypoxia has been shown to result in the translocation of Glut-1 to the plasma membrane [19, 20] . It is reasonable to assume that membranous Glut-1 expression is more important and significant than its cytoplasmic expression when evaluating tumor aggressiveness [21] . In a previous study by Haber et al. [22] , two Glut-1 staining patterns were described on the membranes of thyroid cancer cells: circumferential and asymmetric membranous staining (referred to as luminal accentuation in the present study). According to our results, membranous Glut-1 expression is not related to 18 F-FDG uptake, but membranous Glut-1 expression with luminal accentuation was found to show a marginally significant relationship, which suggests that this pattern of Glut-1 positivity might play a significant role in 18 F-FDG uptake in DTC. SSTRs are often expressed in human endocrine tumors, such as parafollicular C cell-derived medullary thyroid carcinomas, but the expression of SSTR in DTC has rarely been reported and remains controversial. Pisarek et al. [23] reported that SSTR1 and SSTR2A were expressed in 89 and 44 % of Table 4 Relationships between radioiodine scan (RI) and immunohistochemical results (n=19) DTC cases, respectively; however, Druckenthaner et al. [24] reported that SSTR2 was predominantly expressed in DTC. In the present study, the immunoexpression of SSTR1 was more intense than that of SSTR2. Furthermore, in patients with strong SSTR1 expression, only 50 and 60 % showed positive radioiodine uptake and 18 F-FDG uptake, respectively, suggesting that a selective SSTR1-targeted imaging agent might be useful in patients with negative radioiodine uptake or Ga-DOTATOC, target SSTR2 [9, 13, 25] ; we also assessed the expression of SSTR2A, along with SSTR1, to determine whether a radiotracer for SSTR2 imaging could be used for the detection of recurrent PTC. The results of our study showed that the expression of SSTR2A was weaker than that of SSTR1 in enrolled patients, implying that the use of radiotracers for SSTR2 might not be suitable for PTC patients with recurrent neck lymph node metastasis. Furthermore, over 50 % of patients with a negative radioiodine scan (7 of 13 patients) had weak SSTR2A expression, suggesting that SSTR2A expression is correlated with the degree of differentiation in DTC. Radiotracers for SSTR2A would be of limited use for the imaging of less-differentiated DTC with negative radioiodine uptake.
Although NIS expression and Glut-1 expression with luminal accentuation were found to be related to 131 I and 18 F-FDG uptake, respectively, some patients showed negative radioiodine uptake with strong NIS expression, and other showed positive 18 F-FDG uptake with negative or weak membranous Glut-1 expression without luminal accentuation. These findings could be the result of various factors that influence radioiodine uptake or 18 F-FDG uptake. A previous study showed attenuated thyroperoxidase and pendrin expressions in cancers with no 131 I uptake and suggested that low expressions of the genes involved in the radioiodine organification process might result in a short radioiodine retention time and negative findings for these cancers on radioiodine scans [18] . Glut-3 and hexokinase I could also be associated with 18 F-FDG uptake in DTC. Glut-3 expression appears to predominate in more differentiated thyroid tumor cells, whereas Glut-1 overexpression appears to predominate in more de-differentiated thyroid cancers [10] . Additionally, it has also been reported that 18 F-FDG uptake is associated with the overexpression of hexokinase I and that reciprocal staining patterns of NIS and hexokinase I are observed in thyroid cancer cells [19, 26] .
The present study has several limitations. I scans in patients with DTC [27, 28] . Second, only 11 patients underwent both 18 F-FDG PET and radioiodine scans; thus, relationships between the immunohistochemical results and 18 F-FDG PET and radioiodine scans were evaluated separately. Third, because the present study was performed retrospectively, a selection bias is inevitable. Furthermore, the exact location of the metastatic lymph node was not always clearly identified in the surgical reports; therefore, there might be some mismatches between imaging and histopathological findings. Lastly, because of insufficient cancer tissue for immunohistochemical staining in most of metastatic lymph nodes and poor resolution of 131 I scans, a lesion-based analysis could not be performed.
In conclusion, the present study demonstrates that positive radioiodine uptake by recurrent neck nodes is related to the strong expressions of NIS and SSTR2A and that 18 F-FDG uptake is associated with the luminal accentuation of membranous Glut-1 expression. Furthermore, all recurrent cervical nodal lesions with weak Tg expression showed positive 18 F-FDG uptake or negative radioiodine uptake. The evaluations of the expressions of pathological markers in thyroid cancer cells can facilitate choices regarding optimal imaging and therapeutic modalities during the follow-up of thyroid cancer patients with recurrent cervical nodes.
